Alexander Morgan is an MD/PhD physician-scientist and physicist who spent 25 years working at the intersection of AI, biotechnology, and healthcare before becoming a venture capital investor at Khosla Ventures. He oversees the firm's biotechnology and healthcare investments with a deep emphasis on data-driven, AI/ML-enabled biotechnology, and is recognized as one of the most active investors in neurotech startups specifically.

• Deep technical background in bioinformatics and genomics, often referencing his graduate school work with gene expression datasets and microarray analysis. He engages with the nuance of data interpretation, sharing a detailed reflection on how he once analyzed Alzheimer's patient data and wishes he had looked deeper into antiviral transcriptomic patterns rather than dismissing them.
• Focus on translational science that moves from academic labs to commercial application, particularly within the Stanford ecosystem. He highlighted how attending a Grand Rounds talk by Stephen Quake in 2018 directly led to helping start Mirvie, illustrating a long-term commitment to following early scientific research.
• Advocacy for N of 1 therapies and the democratization of advanced medical treatments. He frequently discusses platforms that tailor care to the individual, such as Karius for guiding therapy in critically ill patients or the concept of creating scalable privilege for oncology treatments.
• Strong interest in longevity, healthspan, and preventative medicine. He views statins as the first longevity drug derived from early omics studies and publicly inquires about innovations in reversing age-related conditions like presbyopia.
• Rooted in computer science and algorithm fundamentals. He shared a personal anecdote about reading Michael Sipser's Theory of Computation in a single weekend as a broke student, signaling an appreciation for founders who have a grasp of core computational theories.